The Medical Letter on Drugs and Therapeutics
Cobimetinib (Cotellic) for Metastatic Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib (Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib (Zelboraf) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

STANDARD TREATMENT — BRAF mutations are present in about 50% of melanomas; BRAF V600E accounts for 70-80% of these mutations and BRAF V600K for 5-15%. The BRAF inhibitors vemurafenib and dabrafenib (Tafinlar) have been highly effective in treating BRAF mutation-positive unresectable or metastatic melanoma.1,2 Adding the MEK inhibitor trametinib (Mekinist) improved overall survival compared with use of a BRAF inhibitor alone.3 Immunotherapy with the programmed death receptor-1 (PD-1) inhibitors ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cobimetinib (Cotellic) for Metastatic Melanoma
Article code: 1491c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian